This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

First Patient Treated In Neuralstem China Stem Cell Trial To Treat Stroke Motor Deficits

ROCKVILLE , Md., Jan. 13, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that the first patient was treated in the Phase I/II NSI-566 stem cell trial to treat motor deficits from ischemic stroke at BaYi Brain Hospital in Beijing, China. The patient received treatment on December 27, 2013 and has now returned home. The trial is sponsored by Neuralstem's wholly-owned subsidiary, Neuralstem China (Suzhou Sun-Now Biopharmaceutical Co. Ltd.), which was formed to develop Neuralstem's cell therapy products in China. The stroke motor deficit trial is the first in which Neuralstem's spinal-cord derived stem cells are being transplanted directly into the patient's brain. They are placed near the stroke lesion, where it is hoped they will rebuild damaged neural circuitry and promote repair and recovery. The trial is expected to last two years.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

"We are excited to begin the first trial where the route of administration for our cells is injection into the brain," said Karl Johe, PhD, Neuralstem Chairman and Chief Scientific Officer.  "We would like to thank our colleagues at BaYi, who are making this possible, and the patients who have volunteered for this ground-breaking trial. It is a crucial step forward for the company and the field at large, since optimizing cell therapy treatment for CNS indications will require delivering cells to the brain, as well as to the spinal cord."  

"We are glad to be part of this world-leading clinical research project," said Professor Ruxiang Xu, Chief Physician, BaYi Brain Hospital. " BaYi Brain is a leading neurological medical institution in China with a state-of-the-art facility and advanced medical research and care staff. Through international collaborations, such as the clinical trial of neural stem cells for the treatment of ischemic stroke, we hope to be at the forefront of this new medical paradigm, treating multiple neurological diseases/disorders, such as ischemic stroke, spinal cord injury, ALS, and others, using the most advanced neural stem cells, developed by our U.S. partner, Neuralstem."

In China, alone, it is estimated that over 1,750,000 people per year now survive a stroke. Ischemic stroke, the most common type, occurs as a result of an obstruction within a blood vessel supplying blood to the brain. It accounts for 87% of all stroke cases, according to the American Stroke Association. In the United States, stroke is the fourth-leading cause of death and a leading cause of adult disability, according to the National Stroke Association. Upwards of two-thirds of stroke survivors have some type of disability, according to the National Stroke Association. Post-stroke motor deficits include paralysis in arms and legs, and can be permanent.

About the Trial

The Neuralstem China Phase I/II ischemic stroke trial will enroll up to 118 patients who have suffered an ischemic stroke and have chronic residual motor disorders, between four and 24 months after they have their strokes. The treatment will consist of one-time intracerebral injections of Neuralstem's NSI-566 stem cells into the stroke area using well-accepted stereotactic injection procedures.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs